Varicella-zoster virus antigen-specific immune response induction (None)

The term "Varicella-zoster virus antigen-specific immune response induction" refers broadly to the process by which the human immune system recognizes varicella-zoster virus antigens—either from infection or vaccination—and mounts an adaptive immune defense involving both antibody-producing B cells and cytotoxic/helper T lymphocytes. This includes cytokine signaling cascades that promote Th1-type responses critical for controlling primary infection and preventing reactivation from latency. While essential for recovery from chickenpox/shingles and prevention via vaccination, this is not itself a molecular target suitable for direct pharmacologic modulation—it is instead the desired outcome following exposure to vaccines containing VZV antigens.

Other names

VZV-specific immune response inductionInduction of VZV antigen-specific immunityVaricella-zoster virus adaptive immunity

For vaccines: Induce both humoral and cell-mediated adaptive immune responses specific to VZV antigens by presenting these antigens to T cells and B cells via antigen-presenting cells such as dendritic cells. For antivirals: Inhibit viral replication; do not directly induce antigen-specific immunity, but may reduce viral load allowing natural immune processes to function more effectively.